N-(4-isopropylbenzyloxy)phthalimide | 796061-04-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: N-(4-isopropylbenzyloxy)phthalimide
• 英文别名: 2-[(4-propan-2-ylphenyl)methoxy]isoindole-1,3-dione
• CAS: 796061-04-6
• 化学式: C₁₈H₁₇NO₃
• 分子量: 295.338
• InChiKey: QBVOUIBKSGVCTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(4-isopropylbenzyloxy)phthalimide 在 一水合肼 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 12.33h， 生成 2-[(2E)-4-oxo-2-[(4-propan-2-ylphenyl)methoxyimino]-1,3-thiazolidin-5-yl]acetic acid
  参考文献：
  名称：

  [EN] HUMAN ETS-RELATED GENE (ERG) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE
  [FR] COMPOSÉS DE GÈNES (ERG) ASSOCIÉS À L'ETS HUMAIN UTILISÉS EN TANT QU'AGENTS THÉRAPEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  这项发明提供了具有以下结构的化合物：(I)：(I)。利用这些化合物治疗ERG、FLI1、ETV4或ETV1介导的疾病的用途，包括癌症。还提供了药物组合物和治疗ERG、FLI1、ETV4或ETV1介导的疾病的方法，包括癌症。癌症可以选择自前列腺癌、尤因肉瘤、乳腺癌或胰腺癌等组中的一种。

  公开号：

  WO2018145217A1
• 作为产物：
  描述：

  4-异丙基苯甲醛 在 sodium tetrahydroborate 、 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.0h， 生成 N-(4-isopropylbenzyloxy)phthalimide
  参考文献：
  名称：

  O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1

  摘要：

  Indoleamine 2,3-dioxygenase-1 (IDO1) is a promising therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression. Recently important advances have been made in understanding IDO1's catalytic mechanism. Although much remains to be discovered, there is strong evidence that the mechanism proceeds through a heme-iron bound alkylperoxy transition or intermediate state. Accordingly, we explored stable structural mimics of the alkylperoxy species and provide evidence that such structures do mimic the alkylperoxy transition or intermediate state. We discovered that O-benzylhydroxylamine, a commercially available compound, is a. potent sub-micromolar inhibitor of IDO1. Structure activity studies of over forty derivatives of O-benzylhydroxylamine led to further improvement in inhibitor potency, particularly with the addition of halogen atoms to the meta position of the aromatic ring. The most potent derivatives and the lead, O-benzylhydroxylamine, have high ligand efficiency values, which are considered an important criterion for successful drug development. Notably, two of the most potent compounds demonstrated nanomolar-level cell-based potency and limited toxicity. The combination of the simplicity of the structures of these compounds and their excellent cellular activity makes them quite attractive for biological exploration of IDO1 function and antitumor therapeutic applications. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.12.028

文献信息

• [EN] ESTRATRIENE DERIVATIVES<br/>[FR] DERIVES D'ESTRATRIENE
  申请人：CRYPTOPHARMA PTY LTD

  公开号：WO2004101595A1

  公开（公告）日：2004-11-25

  Compounds and methods for modulating mesenchymal cell function, for instance smooth muscle and fibroblast proliferation or cytokine expression, and for treating conditions associated with mesenchymal cell function, for instance airway hyperresponsiveness associated with asthma. The compounds also supress inflammation. The compounds are a class of estratriene derivates, and includes various derivatives of 2-methoxyestradiol comprising a group A, including a substituted aromatic substituent in the 2-, 6- or 17- position.

  调节间叶细胞功能的化合物和方法，例如平滑肌和成纤维细胞增殖或细胞因子表达，以及治疗与间叶细胞功能相关的疾病，例如与哮喘相关的气道高反应性。这些化合物还抑制炎症。这些化合物是一类雌三烯衍生物，包括各种2-甲氧基雌二醇衍生物，其中包括A组，包括在2-、6-或17-位置有取代芳香基团。
• NOVEL VASCULAR LEAKAGEAGE INHIBITOR
  申请人：Industry-Academic Cooperation Foundation, Yonsei University

  公开号：US20140378399A1

  公开（公告）日：2014-12-25

  The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present invention inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, and enhances the cortical actin ring structure, thereby inhibiting vascular leakage. Accordingly, the vascular leakage inhibitor of the present invention can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present invention is synthesized from commercially available or easily synthesizable pregnenolones, it has remarkably superior feasibility of commercial synthesis.

  本公开涉及一种新型血管渗漏抑制剂。本发明的新型血管渗漏抑制剂抑制血管内皮细胞凋亡，抑制由VEGF诱导的肌动蛋白应激纤维的形成，并增强皮质肌动蛋白环结构，从而抑制血管渗漏。因此，本发明的血管渗漏抑制剂可以预防或治疗由血管渗漏引起的各种疾病。由于本发明的血管渗漏抑制剂是由商业可获得或易于合成的孕酮合成的，因此具有明显优越的商业合成可行性。
• Estratriene Derivatives
  申请人：Stewart George Alastair

  公开号：US20070275935A1

  公开（公告）日：2007-11-29

  Compounds and methods for modulating mesenchymal cell function, for instance smooth muscle and fibroblast proliferation or cytokine expression, and for treating conditions associated with mesenchymal cell function, for instance airway hyperresponsiveness associated with asthma. The compounds also suppress inflammation. The compounds are a class of estratriene derivates, and includes various derivatives of 2-methoxyestradiol comprising a group A, including a substituted aromatic substituent in the 2-, 6- or 17-position.

  化合物和方法用于调节间充质细胞功能，例如平滑肌和成纤维细胞增殖或细胞因子表达，并用于治疗与间充质细胞功能相关的疾病，例如与哮喘相关的气道过度反应。这些化合物还可抑制炎症。这些化合物是一类雌三烯衍生物，包括2-甲氧基雌二醇的各种衍生物，其中包括A组，包括2-，6-或17-位取代芳香基取代物。
• Catalytic <i>Ortho</i>-Acetoxylation of Masked Benzyl Alcohols via an <i>Exo</i>-Directing Mode
  作者：Zhi Ren、Jonathan E. Schulz、Guangbin Dong

  DOI：10.1021/acs.orglett.5b01098

  日期：2015.6.5

  A Pd-catalyzed ortho-acetoxylation of masked benzyl alcohols to synthesize various 2-hydroxyalkylphenol derivatives is reported. The 2,6-dimethoxyl benzaldoxime proved to be an efficient exo-type directing group for arene (sp(2)) CH functionalization. Two strategies were demonstrated to remove the directing group through N-O and C-O bond cleavages. A high catalyst turnover (>1000) was obtained to illustrate the practicality of this method.
• Saczewski, Jaroslaw; Hudson, Alan L.; Rybczynska, Apolonia, Acta poloniae pharmaceutica, 2009, vol. 66, # 6, p. 671 - 680
  作者：Saczewski, Jaroslaw、Hudson, Alan L.、Rybczynska, Apolonia

  DOI：——

  日期：——